• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/12/21 4:32:05 PM ET
    $SBBP
    Major Pharmaceuticals
    Health Care
    Get the next $SBBP alert in real time by email
    SC 13G/A 1 d130776dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    STRONGBRIDGE BIOPHARMA plc

    (Name of Issuer)

    Ordinary shares, par value $0.01 per share

    (Title of Class of Securities)

    G85347105

    (CUSIP Number)

    December 31, 2020

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications:

    Evan K. Hall, Esq.

    Haynes and Boone, LLP

    2323 Victory Avenue, Suite 700

    Dallas, Texas 75219-7673

    (214) 651-5000

     

     

     


    SCHEDULE 13G

     

    CUSIP No. G85347105

     

         

     

      1   

    Names of Reporting Persons

     

    Ikarian Capital, LLC

      2  

    Check the appropriate box if a member of a Group (see instructions)

    (a)  ☐        (b)  ☒

     

      3  

    Sec Use Only

     

        

      4  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

       5    

    Sole Voting Power

     

    0

       6   

    Shared Voting Power

     

    2,440,028

       7   

    Sole Dispositive Power

     

    0

       8   

    Shared Dispositive Power

     

    2,440,028

      9  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,440,028

    10  

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    ☐

    11  

    Percent of class represented by amount in row (9)

     

    3.6% (1)

    12  

    Type of Reporting Person (See Instructions)

     

    IA

     

    (1)

    Based upon 67,243,772 ordinary shares, par value $0.01 per share, outstanding as of October 26, 2020, as disclosed in Form 10-Q filed on October 29, 2020, by the Issuer with the U.S. Securities and Exchange Commission with respect to the quarter ended September 30, 2020.


    SCHEDULE 13G

     

    CUSIP No. G85347105

     

         

     

      1   

    Names of Reporting Persons

     

    Ikarian Healthcare Master Fund, L.P.

      2  

    Check the appropriate box if a member of a Group (see instructions)

    (a)  ☐        (b)  ☒

     

      3  

    Sec Use Only

     

        

      4  

    Citizenship or Place of Organization

     

    Cayman Islands

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

       5    

    Sole Voting Power

     

    0

       6   

    Shared Voting Power

     

    1,845,456

       7   

    Sole Dispositive Power

     

    0

       8   

    Shared Dispositive Power

     

    1,845,456

      9  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,845,456

    10  

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    ☐

    11  

    Percent of class represented by amount in row (9)

     

    2.7% (1)

    12  

    Type of Reporting Person (See Instructions)

     

    PN

     

    (1)

    Based upon 67,243,772 ordinary shares, par value $0.01 per share, outstanding as of October 26, 2020, as disclosed in Form 10-Q filed on October 29, 2020, by the Issuer with the U.S. Securities and Exchange Commission with respect to the quarter ended September 30, 2020.


    SCHEDULE 13G

     

    CUSIP No. G85347105

     

         

     

      1   

    Names of Reporting Persons

     

    Ikarian Healthcare Fund GP, L.P.

      2  

    Check the appropriate box if a member of a Group (see instructions)

    (a)  ☐        (b)  ☒

     

      3  

    Sec Use Only

     

        

      4  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

       5    

    Sole Voting Power

     

    0

       6   

    Shared Voting Power

     

    1,845,456

       7   

    Sole Dispositive Power

     

    0

       8   

    Shared Dispositive Power

     

    1,845,456

      9  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,845,456

    10  

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    ☐

    11  

    Percent of class represented by amount in row (9)

     

    2.7% (1)

    12  

    Type of Reporting Person (See Instructions)

     

    PN

     

    (1)

    Based upon 67,243,772 ordinary shares, par value $0.01 per share, outstanding as of October 26, 2020, as disclosed in Form 10-Q filed on October 29, 2020, by the Issuer with the U.S. Securities and Exchange Commission with respect to the quarter ended September 30, 2020.


    SCHEDULE 13G

     

    CUSIP No. G85347105

     

         

     

      1   

    Names of Reporting Persons

     

    Chart Westcott

      2  

    Check the appropriate box if a member of a Group (see instructions)

    (a)  ☐        (b)  ☒

     

      3  

    Sec Use Only

     

        

      4  

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

       5    

    Sole Voting Power

     

    0

       6   

    Shared Voting Power

     

    2,440,028

       7   

    Sole Dispositive Power

     

    0

       8   

    Shared Dispositive Power

     

    2,440,028

      9  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,440,028

    10  

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    ☐

    11  

    Percent of class represented by amount in row (9)

     

    3.6% (1)

    12  

    Type of Reporting Person (See Instructions)

     

    IN; HC

     

    (1)

    Based upon 67,243,772 ordinary shares, par value $0.01 per share, outstanding as of October 26, 2020, as disclosed in Form 10-Q filed on October 29, 2020, by the Issuer with the U.S. Securities and Exchange Commission with respect to the quarter ended September 30, 2020.


    SCHEDULE 13G

     

    CUSIP No. G85347105

     

         

     

      1   

    Names of Reporting Persons

     

    Neil Shahrestani

      2  

    Check the appropriate box if a member of a Group (see instructions)

    (a)  ☐        (b)  ☒

     

      3  

    Sec Use Only

     

        

      4  

    Citizenship or Place of Organization

     

    United States of America

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

       5    

    Sole Voting Power

     

    0

       6   

    Shared Voting Power

     

    2,440,028

       7   

    Sole Dispositive Power

     

    0

       8   

    Shared Dispositive Power

     

    2,440,028

      9  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,440,028

    10  

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    ☐

    11  

    Percent of class represented by amount in row (9)

     

    3.6% (1)

    12  

    Type of Reporting Person (See Instructions)

     

    IN; HC

     

    (1)

    Based upon 67,243,772 ordinary shares, par value $0.01 per share, outstanding as of October 26, 2020, as disclosed in Form 10-Q filed on October 29, 2020, by the Issuer with the U.S. Securities and Exchange Commission with respect to the quarter ended September 30, 2020.


    Item 1.

     

      (a)

    Name of Issuer:

    STRONGBRIDGE BIOPHARMA plc

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    900 Northbrook Drive, Suite 200, Trevose, PA 19053

     

    Item 2.

     

    (a)

    Name of Person Filing:

    This statement is jointly filed by and on behalf of each of Ikarian Capital, LLC, a Delaware limited liability company (“Ikarian Capital”), Ikarian Healthcare Master Fund, L.P, a Cayman Islands exempted limited partnership (the “Fund”), Ikarian Healthcare Fund GP, L.P., a Delaware limited partnership (“Ikarian GP”), Chart Westcott and Neil Shahrestani (collectively referred herein as the “Reporting Persons”). Ikarian Capital is the investment manager of, and may be deemed to indirectly beneficially own securities owned by, the Fund. Ikarian GP is the general partner of, and may be deemed to indirectly beneficially own securities owned by, the Fund. Ikarian Capital is also the general partner of, and may be deemed to indirectly beneficially own, securities beneficially owned by Ikarian GP. Ikarian Capital is a sub-advisor for certain separate managed accounts (collectively, the “Managed Accounts”) and may be deemed to indirectly beneficially own securities owned by the Managed Accounts. Ikarian Capital is ultimately owned and controlled by Chart Westcott Living Trust, of which Mr. Westcott serves as the sole trustee (the “Trust”), and Mr. Shahrestani. Accordingly, each of Mr. Westcott, as sole trustee of the Trust, and Mr. Shahrestani may be deemed to indirectly beneficially own securities beneficially owned by, Ikarian Capital. The Fund and the Managed Accounts are the record and direct beneficial owners of the securities covered by this statement. The Fund disclaims beneficial ownership of the shares held by the Managed Accounts.

    Each Reporting Person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

    Each Reporting Person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for the purpose of Section 13(d) or 13(g) of the Act. Each of the Reporting Persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purpose of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the issuer or otherwise with respect to the issuer or any securities of the issuer or (ii) a member of any group with respect to the issuer or any securities of the issuer.

     

    (b)

    Address of Principal Business Office or, if None, Residence:

    The address of the principal business office of each of the Reporting Persons is c/o Ikarian Capital, LLC, 100 Crescent Court, Suite 1620, Dallas, Texas 75201.

     

    (c)

    Citizenship:

    See Item 4 on the cover page(s) hereto.


    (d)

    Title and Class of Securities:

    Ordinary shares, par value $0.01 per share

     

    (e)

    CUSIP No.:

    G85347105

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)    ☐    Broker or dealer registered under Section 15 of the Act;
    (b)    ☐    Bank as defined in Section 3(a)(6) of the Act;
    (c)    ☐    Insurance company as defined in Section 3(a)(19) of the Act;
    (d)    ☐    Investment company registered under Section 8 of the Investment Company Act of 1940;
    (e)    ☐    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
    (f)    ☐    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
    (g)    ☐    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
    (h)    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
    (j)    ☐    A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
    (k)    ☐    Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:                    

     

    Item 4.

    Ownership

     

    (a)

    Amount Beneficially Owned as of December 31, 2020: See Item 9 on the cover pages(s) hereto.

     

    (b)

    Percent of Class as of December 31, 2020: See Item 11 on the cover page(s) hereto.

     

    (c)

    As of December 31, 2020, number of shares as to which such person has:

     

      (i)

    Sole power to vote or to direct the vote: See Item 5 on the cover pages hereto.

     

      (ii)

    Shared power to vote or to direct the vote: See Item 6 on the cover pages hereto.

     

      (iii)

    Sole power to dispose or to direct the disposition of: See Item 7 on the cover pages hereto.

     

      (iv)

    Shared power to dispose or to direct the disposition of: See Item 8 on the cover pages hereto.


    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities, check the following  ☒.

     

    Item 6.

    Ownership of more than Five Percent on Behalf of Another Person.

    The information set forth in Item 2(a) is incorporated by reference herein.

     

    Item 7.

    Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

    Not applicable.

     

    Item 8.

    Identification and classification of members of the group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certifications.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 12, 2021

     

    IKARIAN CAPITAL, LLC
    By:   Chart Westcott Living Trust
    Its:   Manager
    By:  

    /s/ Chart Westcott

      Chart Westcott, Trustee
    IKARIAN HEALTHCARE MASTER FUND, L.P.
    By:   Ikarian Healthcare Fund GP, L.P.
    Its:   General Partner
    By:   Ikarian Capital, LLC
    Its:   General Partner
    By:   Chart Westcott Living Trust
    Its:   Manager
    By:  

    /s/ Chart Westcott

      Chart Westcott, Trustee
    IKARIAN HEALTHCARE FUND GP, L.P.
    By:   Ikarian Capital, LLC
    Its:   General Partner
    By:   Chart Westcott Living Trust
    Its:   Manager
    By:  

    /s/ Chart Westcott

      Chart Westcott, Trustee
    CHART WESTCOTT LIVING TRUST
    By:  

    /s/ Chart Westcott

      Chart Westcott, Trustee
    NEIL SHAHRESTANI

    /s/ Neil Shahrestani


    EXHIBIT INDEX

     

    Exhibit

      

    Description of Exhibit

    99.1    Joint Filing Agreement (incorporated herein by reference to Exhibit 99.1 to the Schedule 13G filed on March 19, 2020, by the Reporting Persons with the Securities and Exchange Commission).
    Get the next $SBBP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SBBP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SBBP
    Leadership Updates

    Live Leadership Updates

    See more
    • Axogen, Inc. Appoints John H. Johnson to Board of Directors

      ALACHUA, Fla. and TAMPA, Fla., July 19, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that John H. Johnson has been appointed to its Board of Directors, effective July 19, 2021. Johnson will serve on both the Governance, Nominating and Sustainability Committee and the Science and Technology Committee. Johnson is a recognized leader in the biopharmaceutical industry with more than 30 years of experience in senior leadership positions, including at Johnson & Johnson, Eli Lilly & Company, ImClone, and Centocor Ortho Biotech. "John is an excellent

      7/19/21 4:01:00 PM ET
      $VSTM
      $AXGN
      $SBBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Major Pharmaceuticals

    $SBBP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma

      Xeris Pharmaceuticals, Inc. and Strongbridge Biopharma plc are now subsidiaries of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Xeris Pharmaceuticals, Inc. ("Xeris"), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that it has successfully completed the previously announced acquisition of Strongbridge Biopharma plc (NASDAQ:SBBP) ("Strongbridge"). Under the terms of the acquisition agreement, the businesses of Xeris and Strongbridge are now combined under Xeris Biopharma Holdings, Inc. ("Xeris Biopharma Holdings"). Strongbridge shares and Xeris shares ceased trading on the

      10/5/21 4:05:00 PM ET
      $SBBP
      $XERS
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Strongbridge Biopharma plc Announces Completion of Acquisition by Xeris Pharmaceuticals, Inc.

      DUBLIN, Ireland and TREVOSE, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP) (the "Company" or "Strongbridge") today announced that the High Court of Ireland (the "Court") has approved the previously announced proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) ("Xeris") by means of a scheme of arrangement (the "Scheme") under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the "Act"). The Court sanction hearing in relation to the Scheme was held earlier today at which the Court sanctioned the Scheme and confirmed the related reduction of capital. The Scheme became effective earlier today on October 5, 2021 upon the r

      10/5/21 4:01:00 PM ET
      $SBBP
      $XERS
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Strongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc.

      DUBLIN, Ireland and TREVOSE, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP) (the "Company" or "Strongbridge") today announced that the High Court of Ireland (the "Court") has set the date of the final court hearing to sanction the proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. ("Xeris") by means of scheme of arrangement (the "Scheme") under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the "Act"). The court hearing to sanction the Scheme is scheduled to be heard in the Commercial List of the Court sitting at the Four Courts, Inns Quay, Dublin 7, Ireland at 11:00 a.m. (Irish time) on October 5, 2021, and the Scheme is expected t

      9/23/21 4:01:00 PM ET
      $SBBP
      Major Pharmaceuticals
      Health Care

    $SBBP
    SEC Filings

    See more
    • SEC Form 15-12B filed by Strongbridge Biopharma plc

      15-12B - Strongbridge Biopharma plc (0001634432) (Filer)

      10/15/21 4:16:11 PM ET
      $SBBP
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Strongbridge Biopharma plc

      EFFECT - Strongbridge Biopharma plc (0001634432) (Filer)

      10/7/21 12:15:19 AM ET
      $SBBP
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Strongbridge Biopharma plc

      EFFECT - Strongbridge Biopharma plc (0001634432) (Filer)

      10/7/21 12:15:12 AM ET
      $SBBP
      Major Pharmaceuticals
      Health Care

    $SBBP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Cdk Associates, L.L.C. disposed of 8,060,682 units of Ordinary Shares

      4 - Strongbridge Biopharma plc (0001634432) (Issuer)

      1/5/22 12:43:50 PM ET
      $SBBP
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Wilhoit Scott L. returned 109,510 units of Ordinary Shares to the company, closing all direct ownership in the company

      4 - Strongbridge Biopharma plc (0001634432) (Issuer)

      10/6/21 7:43:10 PM ET
      $SBBP
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Kollender Richard S returned 234,229 units of Ordinary Shares to the company, closing all direct ownership in the company

      4 - Strongbridge Biopharma plc (0001634432) (Issuer)

      10/6/21 7:42:51 PM ET
      $SBBP
      Major Pharmaceuticals
      Health Care

    $SBBP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Strongbridge Biopharma plc (Amendment)

      SC 13D/A - Strongbridge Biopharma plc (0001634432) (Subject)

      1/5/22 12:50:48 PM ET
      $SBBP
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13D/A filed by Strongbridge Biopharma plc (Amendment)

      SC 13D/A - Strongbridge Biopharma plc (0001634432) (Subject)

      10/25/21 12:38:25 PM ET
      $SBBP
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed by Strongbridge Biopharma plc

      SC 13G - Strongbridge Biopharma plc (0001634432) (Subject)

      7/9/21 5:06:20 PM ET
      $SBBP
      Major Pharmaceuticals
      Health Care

    $SBBP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Strongbridge Biopharma downgraded by Craig-Hallum with a new price target

      Craig-Hallum downgraded Strongbridge Biopharma from Buy to Hold and set a new price target of $3.25 from $9.00 previously

      5/25/21 8:44:45 AM ET
      $SBBP
      Major Pharmaceuticals
      Health Care
    • Strongbridge Biopharma downgraded by Craig Hallum

      Craig Hallum downgraded Strongbridge Biopharma from Buy to Hold

      5/25/21 8:00:00 AM ET
      $SBBP
      Major Pharmaceuticals
      Health Care
    • Strongbridge Biopharma downgraded by JMP Securities

      JMP Securities downgraded Strongbridge Biopharma from Outperform to Market Perform

      5/25/21 7:11:31 AM ET
      $SBBP
      Major Pharmaceuticals
      Health Care